OBJECTIVE: In a recent randomized study, we demonstrated that @entity4734 ( @entity901 + oral @entity416 ) was well tolerated and not inferior in terms of efficacy to the infusional FOLFOX-6 regimen in first-line treatment of metastatic @entity14 (mCRC). The objective of this additional analysis was to compare the cost of XELOX and FOLFOX-6. METHODS: This cost-minimisation study took into account costs related to drug acquisition, hospital care for chemotherapy administration and for serious adverse event management. Hospital care costs were based on French 'diagnosis-related group' tariffs. Drug acquisition costs were drawn from French official sources. Analysis was performed from the French health insurance perspective. RESULTS: Baseline characteristics of the 282 @entity1 included (143 XELOX, 139 FOLFOX-6) were well balanced. @entity1 reported less and shorter hospitalisations (day and overnight hospital care) with XELOX: 6.4    2.2 hospitalisations versus 9.7    3.1 (p < 0.001); 11.4    10.6 days versus 17.7    11.8 (p < 0.001). Mean disease management cost per @entity1 was significantly lower with XELOX (EUR 12,918    5,075 vs. EUR 17,229    8,665, p < 0.001). CONCLUSION: In the perspective of our analysis, taking into account hospitalisation and drug acquisition costs, the treatment of mCRC @entity1 with XELOX in comparison to FOLFOX-6 significantly decreased the costs, as well as the mean overall hospitalisation length of stay.

Cost-minimisation analysis in first-line treatment of metastatic XXXX in France: XELOX versus FOLFOX-6.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin'] @entity416 :: ('MESH:C110904', 'Chemical') :: ['capecitabine'] @entity4734 :: ('MESH:C519688', 'Chemical') :: ['XELOX'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer']
@entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']
